Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company
dedicated to advancing the science of analgesia, has received patent
from the United States Patent and Trademark Office (USPTO) for the
composition of matter covering Zorvolex (diclofenac) capsules 18 mg or
35 mg to treat mild to moderate acute pain and osteoarthritis pain.
The patent will be listed in the US Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations publication, or Orange Book. Zorvolex which is approved by the US Food and Drug Administration (FDA) is available at pharmacies across the United States.
“We are excited to receive yet another patent on our flagship product, Zorvolex, which is another testament to our ongoing, successful collaboration with iCeutica,” said Osagie Imasogie, executive chairman of the Board and chief executive officer of Iroko Pharmaceuticals.
The term of the issued patent expires no earlier than 2030. In addition, Zorvolex has three years of regulatory exclusivity from date of product approval through FDA’s regulatory pathway. Iroko and iCeutica continue to prosecute additional patent applications for these and other products in the Iroko portfolio.
The patent will be listed in the US Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations publication, or Orange Book. Zorvolex which is approved by the US Food and Drug Administration (FDA) is available at pharmacies across the United States.
“We are excited to receive yet another patent on our flagship product, Zorvolex, which is another testament to our ongoing, successful collaboration with iCeutica,” said Osagie Imasogie, executive chairman of the Board and chief executive officer of Iroko Pharmaceuticals.
The term of the issued patent expires no earlier than 2030. In addition, Zorvolex has three years of regulatory exclusivity from date of product approval through FDA’s regulatory pathway. Iroko and iCeutica continue to prosecute additional patent applications for these and other products in the Iroko portfolio.
No comments:
Post a Comment